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Background. The results of video-assisted thyroidectomy (VAT) were evaluated in a large series of patients with papillary thyroid
carcinoma (PTC), especially in terms of completeness of the surgical resection and short-to-medium term recurrence. Methods.
The medical records of all patients who underwent video-assisted thyroidectomy for PTC between June 1998 and May 2009 were
reviewed. Results. Three hundred ﬁfty-nine patients were included. One hundred twenty-six patients underwent concomitant
central neck node removal. Final histology showed 285 pT1, 26 pT2, and 48 pT3 PTC. Lymph node metastases were found in 27
cases. Follow-up was completed in 315 patients. Mean postoperative serum thyroglobulin level oﬀ levothyroxine was 5.4ng/mL.
Post operative ultrasonography showed no residual thyroid tissue in all the patients. Mean post-operative 131I uptake was 1.7%.
One patient developed lateral neck recurrence. No other recurrence was observed.
1.Introduction
Over the last decade several techniques for minimally inva-
sive thyroid surgery have been described, including various
endoscopic [1, 2] and video-assisted approaches [3–5]a s
well as minimal incision techniques [6, 7]. The primary
aim of all these diﬀerent approaches has been to improve
the cosmetic results of conventional surgery [8]. Among all
these techniques, video-assisted thyroidectomy (VAT) by the
central access [3, 4] is one of the most diﬀuse worldwide and
it has been adopted by several Centers, especially in Europe
[9–11] and in USA [12].
Initial experiences published on VAT underlined the
advantages of the procedure in terms of a better cosmetic
result and less postoperative pain when compared with
conventional surgery [13–15]. In relatively small series of
patients and comparative studies, VAT has been demon-
strated to be a reproducible, safe and eﬀective technique [3,
4]. Larger multiinstitutional series have fully demonstrated
its safety and eﬃcacy in several clinical settings [9–12]. Sev-
eral advantages of this technique have been clearly demon-
strated: in particular less tissue trauma and less patient
discomfort [13–15]. Furthermore, in one recently published
paper,wedemonstratedthattheincidenceandtheseverityof
early voice and swallowing postthyroidectomy symptoms are
signiﬁcantlyreducedinpatientswhoundergoVATcompared
with those who undergo conventional surgery [16].
In the recent years, VAT has been applied successfully for
the treatment of small papillary thyroid carcinomas (PTC)
[17–20]. Findings of initial small comparative studies have
supported the supposition that VAT allows for a surgical
resection similar in terms of completeness to conventional
surgery [17, 18] with no additional risk of cancer cell seeding
[15]. In spite of these encouraging results, some experts
consider PTC a contraindication for this approach [5, 8],
and some have expressed doubts about its surgical radicality.
Concern has been raised over whether this procedure is
oncologically safe and adaptable beyond the few medical
Centers where it has been developed and optimized [21].
Even though we and others [18, 19] have demonstrated that
VAT allows to obtain the same completeness of the surgical
resection as conventional thyroidectomy in patients with
PTC, some surgeons are still very hesitant to treat PTC by
a video-assisted approach. Additionally, one of the major2 Journal of Oncology
criticism was about the relatively low number of cases and
the absence of an adequate follow-up. Recently Miccoli et al.
[20] have demonstrated, after a quite long period of follow-
up that minimally invasive video-assisted thyroidectomy can
be safely employed in low and intermediate risk patients
without negative impact on patients outcome.
Similarly, video-assisted central compartment lymph
node dissection (VALD = video-assisted lymph node dissec-
tion) has been shown to be feasible with no additional risk of
complicationsinpatientswithPTC[18,22]andinRET-gene
mutation carriers [23].
In this paper, we retrospectively evaluated the results
obtained in a large series of patients who underwent VAT
for PTC over a 10-year period, especially in terms of the
completeness of the surgical resection and short-to-medium
terms recurrence.
2.MaterialsandMethods
Between June 1998 and May 2009, 1356 patients underwent
VAT at the Division of Endocrine Surgery of the Universit` a
Cattolica del Sacro Cuore, Rome, Italy. Eligibility criteria for
VAT were thyroid nodules less than 35 mm on the largest
diameter, an estimated thyroid volume within the normal
range (less than 30mL), and no previous conventional neck
surgeryand/orradiationtherapy.Absolutecontraindications
were malignancies other than PTC and the presence of
preoperatively demonstrated inﬁltrating tumors or lymph
nodemetastases.Allthepatientswhosuccessfullyunderwent
VAT for an histologically proven PTC were included in
this study. The medical records of these patients were
retrospectively reviewed.
The operative technique has been extensively described
in previously published papers [9].
Postoperative serum calcium and phosphorus levels were
measured in all the patients. Hypocalcemia was deﬁned as
a serum calcium level below 8.0mg/dL. Laryngoscopy was
performed preoperatively only in patients that had experi-
enced voice changes and was performed postoperatively in
all patients to check vocal cord motility.
All the patients underwent postoperative suppressive
levothyroxine (LT4) treatment. All patients underwent
serum thyroglobulin (sTg) and anti-Tg antibody measure-
ments under suppressive LT4 treatment and an ultrasound
(US) neck scan 3 to 6 months after surgery. This was the
only follow up protocol adopted for patients with pT1 PTC
≤ 1.0cm, in the absence of lymph node metastases and
multifocality. 131Ia b l a t i o n( R A I )w a sp e r f o r m e do nt h e
basis of stage and risk factors, according to the American
Thyroid Association Guidelines [24]. Low-risk patients were
evaluated by 131I diagnostic whole body scan (DxWBS),
quantitative 131I neck uptake (RAIU) and TSH-stimulated
sTg. All the high risk patients underwent RAI. Posttherapy
whole body scan (TxWBS), RAIU and TSH-stimulated sTg
levels were evaluated in this group of patients.
For the purpose of this paper, the completeness of
the surgical resection was determined by neck ultrasound
imaging, qualitative evaluation with DxWBS or TxWBS,
RAIU, and TSH-stimulated sTg levels.
sTg was measured using a commercial electrochemilu-
minescence immunoassay (ECLIA) (Roche Diagnostic Co.,
Indianapolis, IN, USA) for Elecsys System 2010. The mea-
suring range was 0.100−1000 ng/ml. RAIU was performed by
administering a capsule of 3.7 MBq 131I and 24-h isotope
uptake was measured by an external probe equipped with a
2 ×2cmNaI(Tl)crystal,attachedtoaseries35multichannel
analyser (ACN Monogamma, L’accessorio Nucleare S.r.l.,
Milano, Italy).
RAI required hospitalization and was administered 2−6
months after surgery in hypothyroidism condition (TSH
levels above 30µUI/mL), obtained by withdrawing thyroid
replacement hormone. Pregnancy was excluded before 131I
administration in all women of childbearing age. The 131I
activity was chosen on the basis of a system of “empiric
adjusted doses”. By this system, for example, low activities
(i.e., 1,850GBq) were administered in patients with unifocal
pT1 PTC, no lymph node metastases, and low RAIU values,
while large activities (i.e., 5,550GBq) were chosen for multi-
focal pT3 PTC, with lymph node metastases and high RAIU
values [24, 25]. All patients were subjected to TxWBS before
discharge, 2−5 days after administration of a therapeutic
dose of 131I, to visualize any thyroid remnants or metastases.
Anterior and posterior whole body images were recorded
using a large ﬁeld-of view GE Starcam 3200i scintillation
camera (General Electric Medical System, Milwaukee, WI,
USA), ﬁtted with a high-energy parallel-hole collimator.
Patients who did not receive RAI underwent long-term
follow-up at 6−12 month intervals, at which time US scan
was performed and sTg levels were measured while the
patients were on LT4. Patients whose TxWBS revealed no
thyroid remnants or metastases were also placed on this
follow-up protocol. Patients whose TxWBS revealed thyroid
remnants or metastases were subjected to DxWBS, RAIU
and sTg oﬀ LT4 6−10 months after RAI. The criteria for
successfulthyroidablationweredeﬁnedasthedisappearance
of any visible area of uptake in the thyroid bed, a RAIU
below 1% and undetectable sTg oﬀ LT4 (TSH > 30µUI/mL)
[25]. Patients with complete thyroid remnant ablation, as
deﬁned above, underwent long-term follow-up at intervals
of 6−12 months with sTg measurements taken on LT4 and
USneckscan.Patientswithpartialablationweretreatedwith
additional therapeutic doses of 131I. Tumor stage was deﬁned
according to the American Joint Committee on Cancer [26].
3. Results
Among the 1356 patients who underwent VAT, 370 (27.3%)
were demonstrated by ﬁnal histological examination to have
PTC, and their medical records were reviewed for this paper.
Two hundred and eighty-two out of these 370 patients have
been already reported in a previously published paper [19].
Conversion to an open procedure was required in 2
patients because of intraoperative ﬁndings of gross central
neck and upper mediastinum lymph node metastases. These
patients underwent total thyroidectomy and central neck
dissection (plus lateral neck dissection in one of them). Final
histology showed the tumors to be pT3N1b PTC in both
cases.Journal of Oncology 3
Video-assisted thyroid resection was successfully accom-
plished in 368 patients. Among them, 342 (92.9%) under-
went video-assisted total thyroidectomy as the initial pro-
cedure and the remaining 26 (7.0%) underwent video-
assisted thyroid lobectomy. Among patients in whom a
lobectomy was performed, completion thyroidectomy was
carried out by conventional procedures in 3 cases, which
were operated at the beginning of the experience. Final
histology showed a pT1 PTC in 2 of these cases and a
pT3 in the third case. Six patients had small (<5mm)
pT1 PTC and were followed up after the initial lobectomy.
None of them developed distant or local recurrence. The
remaining 17 patients underwent subsequent video-assisted
completion thyroidectomy. In 359 patients, total thyroid
resectionwasachievedbythevideo-assistedapproach(single
procedure video-assisted total thyroidectomy in 342 cases;
video-assisted thyroid lobectomy followed by video-assisted
completion thyroidectomy in 17 cases). Follow-up data from
these 359 patients were analyzed in this study. There were
323 women and 36 men with a mean age of 43.4 ± 11.2
years (range: 15−79). Preoperative diagnosis was: PTC in
104 cases (29.0%), suspicious nodule in 127 cases (35.4%),
follicular (indeterminate) lesion in 111 cases (30.9%), toxic
multinodular goiter in the remaining 17 (4.7%). The mean
maximum diameter of the lesion evaluated preoperatively by
US scan was 17.3 ± 6.3mm (range: 6−35).
A video-assisted lymph node dissection was deemed
necessary in 126 patients, 94 of whom were preoperatively
diagnosed with small PTC or suspicious nodules and
underwent a selective central node removal of enlarged
lymph nodes; the remaining 32 of these patients received a
complete video-assisted central compartment lymph node
dissection (CCD = Central Compartment Dissection or level
VI neck node dissection). The mean number of lymph nodes
removed during VALD was 6 ± 4.06 (range: 1−19). The mean
number of removed nodes in the CCD subgroup was 9.2
± 3.7 (range: 6−19). Concomitant parathyroidectomy for a
parathyroid adenoma was performed in 7 patients.
Mean operative time was 63.1 ± 27.3 min for lobectomy
(range: 30−150), 66.9 ± 22.6 min for total thyroidectomy
(range: 30−220), and 54.4 ± 24.9 min for completion
thyroidectomy (range: 30−100). Mean operative time for
CCD was 17.7 ± 3.4 min (range:12−22).
Final histology revealed 285 pT1 PTC diagnoses (multi-
focalin80cases),26pT2diagnoses(multifocalin10),and48
pT3 diagnoses (multifocal in 16). One hundred ﬁfty six out
ofthe285pT1PTChadamaximumdiameter<1cm.Among
them 94 were diagnosed preoperatively. The remaining 62
cases had an incidental diagnosis of microcarcinoma. Lymph
node metastases were found in 24 of the cases in which CCD
was performed, including 3 cases of micrometastases and
also in three case in which selective central node dissection
was performed. Reactive changes were evident in the lymph
nodes removed from the other 97 patients who underwent
selective central node dissections. In patients with lymph
node metastases (N1a), the primary tumor was pT1 in 15
cases and pT3 in 12 cases.
Post-operative complications included 11 transient re-
currentnervepalsies(1.5%ofthenervesatrisk),90transient
hypocalcaemia cases (25%), 4 permanent hyperparathy-
roidism cases (1.1%) and 1 postoperative hematoma (0.4%).
Mean postoperative stay was 3.1 ± 1d a y s( r a n g e :2 −7).
Completefollow-updatawereavailablein315(87.7%)of
the 359 patients included in the study; 246 of these had pT1
t u m o r s ,2 2h a dp T 2t u m o r s ,a n d4 7h a dp T 3t u m o r s .T h e
mean follow-up period was 21.5 ± 5.9 months (range: 5−40).
In 137 of these patients (38.2%) with pT1 PTC <1.0cm,
in the absence of lymph node metastases and multifocality,
follow-up evaluation included sTg measurements on LT4
and ultrasonography. sTg was undetectable (<0.1ng/mL)
and the US neck scan showed no thyroid remnants or lymph
node involvement in all these cases.
Fortheremaining178patientspostoperativeultrasonog-
raphy showed no residual thyroid tissue; mean sTg after
LT4 withdrawal was 5.4 ± 7.5ng/mL (range 0.1−31.4); sTg
was undetectable (<0.1ng/mL) in 33 patients (18.5%); mean
RAIU was 1.7 ± 2.6% (range: 0−18.2%). RAIU was <0.5%
in 33 (18.5%) of the patients and <1% in 74 (41.5%) of the
patients. In the 27 patients with lymph node metastases, sTg
oﬀLT4 was 4.6 ±4.6ng/mL(range:0.44−13)andmeanRAIU
was 1.8 ± 0.8% (range: 1.2−3.4%).
Visual TxWBS evaluation demonstrated thyroid rem-
nants and coexisting lymph node metastases in one high-
risk patient. This last patient required a conventional lateral
neck dissection after unsuccessful RAI two years after the
initial surgery. TxWBS after the second operation showed no
residual uptake.
4. Discussion
Among the indications for VAT, nodule size together with
thyroid volume are the most important selection’s limiting
factors. For this reason, small suspicious or malignant
nodules are, from a technical point of view, one of the
best indications for VAT. However at the beginning of the
experience there were some concerns about the feasibility
andsafetyofVATincaseofmalignancy.Nonetheless,afteran
adequate experience being achieved, this technique has now
been proposed as a valid alternative to conventional surgery
also for the resection of small PTC [17–20].
It has been supposed that manipulation and extraction
of the thyroid gland through a small skin incision might
increase the risk of thyroid capsule rupture, with possible
cell seeding. However, we have previously demonstrated that
thyroid gland manipulation does not diﬀer between VAT
and conventional surgery and that VAT does not confer
additional risk of thyroid capsule rupture and cell seeding
[15].
Another important concern about VAT is whether the
surgical resection obtained with this approach is suﬃciently
complete. Previous studies suggested that the surgical radi-
cality of VAT (as evaluated by postoperative sTg on and oﬀ
LT4, ultrasound scan and RAIU) is comparable to that of
conventional surgery [17–20]. The present study conﬁrmed
in a larger patient cohort that VAT allows for an adequate
surgical resection in case of small PTC.
STg on LT4 suppression therapy was undetectable in
most of the patients. After LT4 withdrawal (TSH > 30 UI/l),4 Journal of Oncology
mean sTg level was low (5.4ng/mL) and even undetectable
in many patients.
Another point to take into account is the possibility to
perform a central neck node clearance by the video-assisted
approach. It is well know that even though up to 80% of
patients with PTC could have at least microscopic metastatic
spread to cervical lymph nodes, this does not seem to aﬀect
prognosis, at least in patients younger than 45 years. For this
reason prophylactic neck dissection for this group of patients
is not recommended [27]. We [19, 22] and others [23]h a v e
demonstrated that removal of unexpectedly enlarged central
compartment lymph nodes is feasible and safe by video-
assisted approach. The endoscope allows for meticulous
exploration of the central compartment and quite easy
identiﬁcation of even slightly enlarged lymph nodes. At the
same time, thanks to the magniﬁcation of the endoscope,
good exposition of the operative ﬁeld and of the neck
structures permits careful dissection and safe preservation of
the inferior laryngeal nerve and the parathyroid glands.
The mean number of lymph nodes removed in patients
who underwent CCD demonstrates that it is possible to
achieve satisfactory clearance of the central compartment.
The incidence of central compartment node metastasis
among the patients who underwent complete video-assisted
CCD was comparable to the rates reported in the literature
(11%−80%) [28].
Postoperative evaluation by sTg on and oﬀ LT4, US neck
scan and RAIU tests conﬁrmed that it is possible to obtain
adequate surgical resection by the VAT approach, even in
patients with central compartment lymph node metastases.
The results of the present study conﬁrm our previous
reports and are in agreement with a recently published
paper. Indeed, Miccoli et al. [20] demonstrated that the
completeness of the surgical resection is similar for both
VAT and conventional surgery even in patient with minimal
lymph node involvement (“intermediate risk”).
Mean follow-up time was about 2 years, with the longest
follow-up of about 3 years. This could be considered the
main limitations of this paper, which is probably inadequate
to assess the long-term recurrence rate of PTC, considering
its indolent nature.
Indeed, depending on the initial treatment and on other
prognostic variables, 30% of patients with PTC will have
recurrence over several decades, with about two-thirds of the
recurrences occurring within the ﬁrst 10 years after initial
therapy [29]. In the present series, we observed only one
caseoflateralneckmetastaseswhichappearedaftertwoyears
after the initial video-assisted thyroidectomy. This further
conﬁrm the adequacy of VAT for the treatment of small PTC.
On the basis of the previous consideration, eligibility
criteria for VAT are: thyroid nodules <35mm; thyroid
volume <30mL; no previous conventional neck surgery
and/or radiation therapy and small, low- to intermediate-
risk, papillary thyroid carcinomas (PTC).
Concerns remain regarding the precise indications for
lymph nodes dissection by video-assisted approach. It would
be prudent to continue to perform central neck dissection
only in case of enlarged central compartment lymph nodes,
unexpectedly discovered during VAT for PTC or suspicious
nodules, or in case of prophylactic central neck node
clearance, when required. Conversion to the conventional
approach is mandatory if node clearance is not as accurate as
in conventional surgery. Overt lymph node involvement still
remains a contraindication for video-assisted procedures.
5. Conclusions
In conclusion, this study conﬁrms that VAT is feasible and
safe procedure for surgical treatment of small PTC. If
selection criteria are strictly followed, it seems equivalent
to conventional surgery in terms of completeness of the
surgical resection. VAT can be considered a valid alternative
to conventional surgery also for the treatment of small PTC,
in absence of any clinical or instrumental sign of local
invasion or lymph node involvement.
Nonetheless, longer follow-up evaluation could further
validateitsoncologicresults,especiallyintermsofrecurrence
rates.
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